T Helper Cells and Cytokine Networks in the Immunopathogenesis of Multiple Sclerosis

Abstract

Abstract: Multiple sclerosis (MS) is a chronic autoimmune disorder of CNS with demyelination, neurodegeneration and compartmentalized inflammatory disorder. Excessive T-helper cell (CD4 + ) activation and unregulated cytokine signaling play a key role in its onset and progression. These changes impair communication between peripheral immune cells and CNS resident microglia, astrocytes and oligodendrocytes. This review provides an overview on the contribution of specific subsets of T-helper cells to MS pathology/immunity. Th1 cells release interferon-γ and lymphotoxin, that stimulate activation of myeloid cells/antigen presentation. Activated by IL-23, the Th17 cells produce IL-17A/F that lowers the blood–brain barrier (BBB) integrity, recruit neutrophils and monocytes, and enhance microglial killing. Activation of CD4 + T cells leads to activation of B cells via T follicular helper cells which couple these processes through the production of IL-21 and CXCR5. This leads to the development of tissue-like aggregates and intrathecal antibody production. T-cell plasticity adds to epitope spreading as well as chronic inflammation, IL-22, IL-9, IL-1β, IL-6, and TGF-β (these are additional mediators involved in the regulation of effector phenotypes). In MS, the regulation of dendritic cell co-stimulation and of glial activation often does not work. This is due to the lack of control of dendritic-cells co-stimulation and the lack of regulation of glial activation by regulatory pathways such as FOXP3 + regulatory T cells and Tr1 cells that secrete IL-10 and TGF-Beta. The review also explores the cytokine network biomarkers, CSF and serum signatures and single-cell immune states, as well as existing and new drugs. These include migration blockade, targeting of S1P-receptors, anti-CD20 therapy, targeting of Th17/GM-CSF and JAK–STAT pathways, low-dose IL-2, approaches of targeting antigens and engineered Tregs. Investigating the areas of stage and compartment-specific CD4 + T-cell circuits can help to advance targeted immunomodulation in progressive MS and neuro-repair. The diagram illustrates central nervous system immunopathology. It begins with blood-brain barrier disruption, where pro-inflammatory cytokines weaken the barrier, promoting immune cell infiltration. T helper cells, including Th1, Th17 and Tm1, are shown with cytokines like interferon gamma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor and interleukin 22. Microglial activation and immune-mediated damage involve B cells and lead to myelin and axonal damage. Therapeutic strategies include migration blockade using integrin antagonism and cytokine blockade targeting interferon gamma, interleukin 17, granulocyte-macrophage colony-stimulating factor and interleukin 6. T regulatory cells are influenced by interleukin 10 and transforming growth factor beta, promoting immune regulation.CNS immunopathology: BBB disruption, T cells, microglial activation, therapy strategies. Keywords: multiple sclerosis, central nervous system, T-Lymphocytes, helper-inducer, cytokines, neuroinflammatory diseases, autoimmunity